A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).

NCT00838357 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma (Non-Hodgkin's Lymphoma)
Hodgkin's Disease or Multiple Myeloma
Front Line Mobilization
Transplantation

Interventions

DRUG: Generic = Plerixafor

Sponsor

Genzyme, a Sanofi Company